Vadodara-based integrated pharma maker of branded generics, US/global formulations and APIs across 10 plants.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 38 | 39 | 39 | 39 | 39 | 39 | 39 | 39 |
| Reserves | 3.2k | 5.0k | 5.2k | 4.3k | 4.8k | 5.2k | 5.3k | 5.6k |
| Borrowings | 1.7k | 584 | 717 | 722 | 513 | 1.3k | 1.5k | 1.4k |
| Other Liabilities | 1.0k | 1.1k | 1.2k | 1.1k | 1.1k | 1.3k | 1.6k | 1.7k |
| Total Liabilities | 6.0k | 6.7k | 7.1k | 6.2k | 6.4k | 7.8k | 8.4k | 8.8k |
| AssetsFixed Assets | 1.6k | 1.8k | 1.8k | 2.4k | 2.5k | 2.5k | 2.8k | 3.1k |
| CWIP | 1.8k | 2.2k | 2.3k | 601 | 524 | 837 | 903 | 683 |
| Investments | 18 | 236 | 118 | 96 | 93 | 127 | 129 | 141 |
| Other Assets | 2.6k | 2.5k | 2.9k | 3.1k | 3.3k | 4.3k | 4.5k | 4.9k |
| Total Assets | 6.0k | 6.7k | 7.1k | 6.2k | 6.4k | 7.8k | 8.4k | 8.8k |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 812 | 449 | 1.5k | 552 | 724 | 803 | 88 | 783 |
| Cash from Investing | -756 | -731 | -840 | -372 | -448 | -321 | -568 | -506 |
| Cash from Financing | 59 | 155 | -597 | -217 | -262 | -438 | 444 | -164 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 49 | -285 | 804 | 128 | 282 | 487 | -466 | 290 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (28.5×) and current (24.0×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 25.3% growth and a 24× exit, ₹825 only delivers your return if you pay ₹1,172. The price is currently baking in 18% growth.
EPS grows 25.3%/yr for 5 years, then fades to 6% over 2, exits at 24×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 25.3% | 43.00 |
| FY28 | 25.3% | 53.88 |
| FY29 | 25.3% | 67.52 |
| FY30 | 25.3% | 84.60 |
| FY31 | 25.3% | 106.00 |
| FY32 | 15.7% ·fade | 122.59 |
| FY33 | 6.0% ·fade | 129.94 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.